Integrated Center for Oncology

Breast Cancer Gene-Expression Miner v5.0
(bc-GenExMiner v5.0)

bc-GenExMiner logo


TNBC (IHC) subtypes prognostic analysis Tutorial

Enter input gene and choose one of the following options:

  • GENE EXPRESSION DATA Open
  • This analysis is only available with all DNA microarrays data.
    This option allows to explore triple-negative breast cancer (TNBC) (IHC) subtypes (LAR, MLIA, BLIA and BLIS):
    • LAR: luminal androgen receptor,
    • MLIA: mesenchymal-like immune-activated,
    • BLIA: basal-like immune-activated,
    • BLIS: basal-like immune-suppressed.

  • DNA microarrays
  • (n = 1 243)
  • (n = 693)
  • (n = 276)
  • RNA-seq
  • (n = 699)
  • (n = 87)
  • (n = 206)

  • POPULATION Open
  • All kind of event used for survival analyses will be taken into account:
    • "distant metastasis-free survival" (DMFS): first pejorative event represented by distant relapse.
    • "overall survival" (OS): first pejorative event represented by death.
    • "disease-free survival" (DFS): first pejorative event represented by any relapse or death.
    These datasets are retrieved from published annotated transcriptomic data.

  • Event status:
  • All time-to-event endpoints will be taken into account
    (DMFS, OS and DFS).
  • DISCRETISATION Open
  • Choose one of the radio button to select which splitting method you want to explore for prognostic study:
    • "mediane": 2 groups split at 50%,
    • "tertile": 3 groups split at 33%,
    • "quartile": 4 groups split at 25%,
    • "optimal": 2 groups split at the best cut-off (more details)
    • "custom percentile": 2 groups split at the user cut-off.

  • Splitting criterion:


  • Legend Open

     DFS:disease-free survival
     DMFS:distant metastasis-free survival
     IHC:immunohistochemistry
     OS:overall survival (any relapse or death)
     TNBC:triple-negative breast cancer; tumours negative for oestrogen and progesterone receptors and epidermal growth factor receptor 2 (HER2), by means of IHC



    © 2010 About us    Contact Last update June 28th, 2023 Disclaimer Site map
    2024